Study of SRF388 in Patients With Advanced Solid Tumors

Study Number

777920

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.

Check your eligibility for this trial

Check now

Full Title

A Phase 1 Study of SRF388 in Patients with Advanced Solid tumors

ClinicalTrials.Gov ID

NCT04374877

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.